{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:05:12Z","timestamp":1779113112851,"version":"3.51.4"},"reference-count":3,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Care"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>Introduction: This real-world study assessed the breast cancer susceptibility gene 1 or 2 mutation (BRCA1\/2mut) status on treatment patterns, safety, and patient-reported outcomes (PROs) in women with human epidermal growth factor receptor 2-negative (HER2\u2212) advanced breast cancer (ABC) in the USA, the UK, and EU4 countries. Methods: Oncologists abstracted data from medical charts of adult women who presented with HER2\u2212 ABC from February to May 2015 and from March to July 2017. Data were collected using a physician-reported form and a patient-reported form, which included questions on breast cancer history\/treatment and questions from PRO instruments (EuroQol 5-Dimensions 3-Levels [EQ-5D-3L], Brief Pain Inventory [BPI], European Organisation for Research and Treatment of Cancer [EORTC] Quality of Life Questionnaire Core 30 and its breast cancer module). Results: In total, 742 oncologists provided data for 6,161 patients; 27.5% were tested for BRCA1\/2mut. Out of the total patient population, 3.8% had BRCA1\/2mut, 16.6% BRCA1\/2 wild-type (BRCA1\/2wt), and 79.5% were BRCA1\/2 unknown (BRCA1\/2unk). Hormone receptor-positive (HR+)\/HER2\u2212 ABC was more frequent within the BRCA1\/2wt versus BRCA1\/2mut group and triple-negative breast cancer (TNBC) within the BRCA1\/2mut versus BRCA1\/2wt group. More patients with HR+\/HER2\u2212 ABC with BRCA1\/2mut received chemotherapy (with or without targeted or endocrine therapy) versus BRCA1\/2wt (66.0% vs. 50.4%; p &lt; 0.01); more patients had \u22651 AE (58.0% vs. 39.1%; p &lt; 0.001). Among patients with BRCA1\/2mut versus BRCA1\/2wt, a significantly higher proportion had some problems or worse pain discomfort (p = 0.021) and anxiety\/depression (p = 0.007) as measured by the EQ-5D-3L; role functioning (p &lt; 0.01) and dyspnea (p &lt; 0.05) measured by EORTC were worse with BRCA1\/2mut. Pain scores by BPI were similar between groups. Conclusions: In patients with HER2\u2212 ABC in the real-world setting, more patients with BRCA1\/2mut had TNBC; received chemotherapy; had &gt;1 AE; and experienced increased discomfort, anxiety, and dyspnea and diminished role functioning versus patients with BRCA1\/2wt.<\/jats:p>","DOI":"10.1159\/000523970","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T17:00:34Z","timestamp":1647018034000},"page":"460-469","source":"Crossref","is-referenced-by-count":6,"title":["Treatment Patterns, Safety, and Patient Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without, or with Unknown, BRCA1\/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and four EU Countries"],"prefix":"10.1159","volume":"17","author":[{"given":"Michael Patrick","family":"Lux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Niyazov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.632079"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0414"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2217\/fon.13.278"}],"updated-by":[{"DOI":"10.1159\/000525366","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000}}],"container-title":["Breast Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/brc\/article-pdf\/17\/5\/460\/4021762\/000523970.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/brc\/article-pdf\/17\/5\/460\/4021762\/000523970.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:56:36Z","timestamp":1745409396000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000523970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":3,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,11,17]]}},"URL":"https:\/\/doi.org\/10.1159\/000523970","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.19344932","asserted-by":"subject"},{"id-type":"doi","id":"10.1159\/000525366","asserted-by":"object"}]},"ISSN":["1661-3791","1661-3805"],"issn-type":[{"value":"1661-3791","type":"print"},{"value":"1661-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}